EHA Library - The official digital education library of European Hematology Association (EHA)

THE RELATIONSHIP BETWEEN PLATELET SPECIFIC ANTIBODIES AND THE SEVERITY OF NEWLY DIAGNOSED PEDIATRIC ITP
Author(s):
Shuyue Dong
Affiliations:
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,Chine;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,Cina;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,China;Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China,Beijing,Kina
EHA Library. dong S. 06/10/22; 359150; PB2298
Shuyue dong
Shuyue dong
Contributions
Abstract
References

Abstract: PB2298

Type: Publication Only

Session title: Platelet disorders

Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction. 

Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the severity of newly diagnosed pediatric ITP.

Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. Children who used only glucocorticoids during hospitalization were defined as Severity 1. Children who used glucocorticoids combined with intravenous immunoglobulin (IVIG) and/or single rhTPO were defined as Severity 2. Platelet specific antibodies were detected by PAKAUTO.

Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIIb/IIIa antibody are more severe than children with negative anti-GPIIb/IIIa antibody in newly diagnosed ITP (c2=3.969, P=0.046). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the severity of newly diagnosed pediatric ITP.

Conclusion
Anti-GPIIb/IIIa antibody is a sign of higher severity in newly diagnosed pediatric ITP. anti-GPIb/IX and anti-GPIa/IIa antibodies were not found to be related to the severity of ITP.

Keyword(s): Antibody, Clinical data, Immune thrombocytopenia (ITP)

Abstract: PB2298

Type: Publication Only

Session title: Platelet disorders

Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction. 

Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the severity of newly diagnosed pediatric ITP.

Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. Children who used only glucocorticoids during hospitalization were defined as Severity 1. Children who used glucocorticoids combined with intravenous immunoglobulin (IVIG) and/or single rhTPO were defined as Severity 2. Platelet specific antibodies were detected by PAKAUTO.

Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIIb/IIIa antibody are more severe than children with negative anti-GPIIb/IIIa antibody in newly diagnosed ITP (c2=3.969, P=0.046). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the severity of newly diagnosed pediatric ITP.

Conclusion
Anti-GPIIb/IIIa antibody is a sign of higher severity in newly diagnosed pediatric ITP. anti-GPIb/IX and anti-GPIa/IIa antibodies were not found to be related to the severity of ITP.

Keyword(s): Antibody, Clinical data, Immune thrombocytopenia (ITP)

Abstract: PB2298

Type: Publication Only

Session title: Platelet disorders

Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction. 

Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the severity of newly diagnosed pediatric ITP.

Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. Children who used only glucocorticoids during hospitalization were defined as Severity 1. Children who used glucocorticoids combined with intravenous immunoglobulin (IVIG) and/or single rhTPO were defined as Severity 2. Platelet specific antibodies were detected by PAKAUTO.

Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIIb/IIIa antibody are more severe than children with negative anti-GPIIb/IIIa antibody in newly diagnosed ITP (c2=3.969, P=0.046). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the severity of newly diagnosed pediatric ITP.

Conclusion
Anti-GPIIb/IIIa antibody is a sign of higher severity in newly diagnosed pediatric ITP. anti-GPIb/IX and anti-GPIa/IIa antibodies were not found to be related to the severity of ITP.

Keyword(s): Antibody, Clinical data, Immune thrombocytopenia (ITP)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies